DNA Methylation and Urothelial Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01378052|
Recruitment Status : Unknown
Verified June 2011 by China Medical University Hospital.
Recruitment status was: Recruiting
First Posted : June 22, 2011
Last Update Posted : June 22, 2011
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Observational Model:||Case Control|
|Official Title:||Level of DNA Methylation in People With Urothelial Carcinoma|
|Study Start Date :||June 2011|
|Estimated Primary Completion Date :||June 2012|
|urothelial carcinoma pateints|
Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
- urothelial carcinoma [ Time Frame: one year ]Pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01378052
|Contact: Chao-Hsiang Chang, PhD||886-4-22052121 ext email@example.com|
|Department of Urology, China Medical University Hospital||Recruiting|
|Taichung, 404, Taiwan|
|Contact: Chao-Hsiang Chuang, PhD 886-4-22052121 ext 4439 firstname.lastname@example.org|
|Principal Investigator:||Chi-Jung Chung, PhD||Department of Health risk Management, China Medical University|